AP24534 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) granted Orphan Drug designation to Ariad's AP24534 to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). The oral B...